POSC325 Use of the New French ‘Organizational Impact Map’ Published by the Haute Autorité de Santé (HAS) to Evaluate the Organizational Impact of Immune-Checkpoint Inhibitors in Advanced Cancers

Abstract

Authors

V Grumberg C Chouaid FE Cotte AF Gaudin I Borget

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×